Pyxis Oncology Announces $110 Million Public Offering, Shares Drop
Pyxis Oncology (PYXS) has priced a registered public offering expected to generate approximately $110 million in gross proceeds. The company plans to issue 36.05 million shares as part of the offering. Following the announcement, PYXS stock fell by about 8.8% during after-hours trading, reaching around $2.64 per share. The decline suggests investor skepticism or caution regarding the capital raise and its implications for company operations or valuation. The public offering is likely intended to fund ongoing research, development, or operational needs of Pyxis Oncology.
Tickers: $PYXS